Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found evidence suggesting that androgenic alopecia may be associated with increased cardiovascular risk factors, but noted a lack of comprehensive research on scarring alopecias and cardiovascular disease.

Low-dose oral naltrexone may help reduce inflammation in some scarring alopecia patients.

This case report describes a 39-year-old female with cutis verticis gyrata and cicatricial alopecia, emphasizing the need for further understanding of the potential genetic associations and underlying mechanisms.

This case report identified a distinct pattern of scarring alopecia with folliculocentric noncaseating granulomas, linked with granulomatous dermatitis in the breast, as a potential cutaneous manifestation of rheumatoid arthritis.

This study reviews treatments for scarring alopecia, highlighting that the primary approach focuses on reducing inflammation and preventing progression, with corticosteroids as a common initial treatment.

This research observed that EGFR activity appears to maintain hair follicle quiescence and immune privilege, and its inhibition may lead to stem cell apoptosis and scarring alopecia during inflammation.

This case study highlights the rare occurrence of scarring and nonscarring alopecia following vascular occlusion from dermal filler injections, with the researchers suggesting that a combined treatment including hydroxychloroquine might improve outcomes for this complication.

This study reported that in mouse models, deletion of EGFR resulted in stem cell hyper-proliferation followed by apoptosis, leading to scarring alopecia, and implicated EGFR's role in maintaining hair follicle quiescence and immune privilege during inflammation.

This study found that patients receiving PRP treatments for various types of alopecia and skin rejuvenation had a higher risk of adverse events and lower self-assessment scores when injections were administered at shallower depths, with significant correlations between patient and physician assessments across different indications.

This study suggests that the expression and localization of toll-like receptors and caveolin-1 in lichen planopilaris may influence cicatricial alopecia pathobiology and that downregulating caveolae could offer a novel management strategy.

This case study reports a rare presentation of cutaneous sarcoidosis on the scalp, evidenced by scarring alopecia linked to non-caseating granulomas in a 48-year-old female with uveitis.

This study identified discoid lupus erythematosus and pseudopelade of Brocq as the leading causes of scarring alopecia, highlighting the importance of skin punch biopsy for accurate diagnosis.

This letter discusses the potential benefits of vitamin D supplementation for scarring and nonscarring alopecia but notes a lack of standard trials to support its use.

Following treatment plans is crucial to prevent worsening skin and hair conditions.

This paper presents two cases of frontal fibrosing alopecia in postmenopausal women, noting challenges in monitoring due to the invasive nature of the diagnostic process.

This case report describes a novel instance of scarring alopecia with features of frontal fibrosing alopecia in a patient with systemic sclerosis, suggesting a potential link between the two conditions not previously reported.

This review examines recent advancements in topical formulations for alopecia treatment, but it reports no new clinical results, emphasizing potential strategies to enhance drug delivery to the scalp.

In this case study, a 69-year-old woman with pityriasis rubra pilaris developed a scarring alopecia with lichen-planopilaris-like features, which responded well to early treatment.

This study found that fibrosis-associated trochanters in central centrifugal cicatricial alopecia are enriched with hair follicle stem cells and may indicate a disrupted stem cell niche contributing to scarring.

This study suggests that hormone replacement therapy and oral contraception may have a protective role in scarring alopecia, as these were reported less frequently by patients with the condition compared to those with female pattern hair loss.

This study found that the PPAR-γ modulator AGED can reverse epithelial-mesenchymal transition in hair follicles affected by lichen planopilaris ex vivo, suggesting potential for treating scarring alopecias.

This study shows that multiphoton microscopy can non-invasively distinguish scarring from non-scarring alopecia by identifying specific morphological features in hair follicle structures.

This study found that N-acetyl-GED may protect and partially rescue human hair follicles from experimentally-induced epithelial-mesenchymal transition ex vivo, suggesting its potential in treating scarring alopecias like lichen planopilaris.

Treatment improved some symptoms but not all.

This abstract discusses the classification of scarring alopecia, distinguishing it from secondary scarring alopecia and detailing its subtypes based on inflammation patterns and cells present during the disease's active phase, but reports no new clinical results.

Chemical relaxers may cause scarring alopecia in black women.

This study suggests that decreased PPARgamma function may trigger the pathogenesis of lichen planopilaris, and PPARgamma-targeted therapy could be a potential treatment method.

Tinea can cause scarring alopecia in children, and fungal culture is crucial for diagnosis.

The woman was diagnosed with lichen planopilaris and can be treated with corticosteroids.

In this study, a new technique using a punch-out method followed by resuturing was shown to improve the appearance of widened scars from previous hair transplant procedures in 58 patients, with the advantages of being quick and not requiring additional follicular units.